OBJECTIVES: To evaluate patient satisfaction with golimumab (GLM) and its auto-injector in rheumatoid arthritis (RA) patients switched from adalimumab (ADA) or etanercept (ETA) due to inadequate disease control. METHODS: Data were from an interim analysis of 200 patients enrolled in GO-SAVE, a GLM multicenter, assessor-blinded, switch study of patients with active RA. Patients receiving methotrexate and having an inadequate response to current treatment with ADA or ETA entered the screening period at week -6 and continued current treatment. After re-screening at week 0, all eligible patients were actively switched to open-label GLM 50mg subcutaneous injections.  Satisfaction prior to switching was assessed at week -2 for ADA or week -1 for ETA.  Satisfaction with and preference for GLM were assessed at week 8.  RESULTS: Mean (SD) age was 55.9 (11.3) years; 81.5% were female. Mean (SD) disease duration was 9.8 (9.7) years. Prior to switch, patients were treated with ADA pen (25.5%), ADA prefilled syringe (21.5%), ETA pen (27%), ETA prefilled syringe (24%), and ETA vial and syringe (2.0%). All 200 patients completed assessment at week -2 (ADA) or -1 (ETA); 170 completed the assessment at week 8 (GLM). At week 8, 82.9% were satisfied with the overall GLM experience, 80.0% were satisfied with injection frequency, and 75.3% were satisfied with injection device.  Most patients experienced lower levels of injection related burning (80.0%), stinging (75.3%), discomfort (62.4%), redness (58.8%), and pain (57.6%) with the GLM auto-injector than with the previous injection device.  Patients expressed greater preference for GLM over their previous medication (74.0%) and greater preference for the auto-injector (70.6%) over their previous injection device. CONCLUSIONS: A majority of RA patients switched to GLM from ADA or ETA were satisfied with their overall GLM experience, including preference for GLM and the auto-injector over previous medication and injection device.